 |
|
|
|
 | Vertex Pharmaceuticals Inc (NASDAQ GS:VRTX) | 9/3/2010 |  |
| TUESDAY, AUGUST 10, 2010 | | 4:15 PM | Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Genuity 30th Annual Growth Conference - BusinessWire |  | | 7:00 AM | Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment - BusinessWire | | | WEDNESDAY, JULY 28, 2010 | | 4:01 PM | Vertex Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress - BusinessWire | | | TUESDAY, JULY 13, 2010 | | 4:01 PM | Vertex Pharmaceuticals Appoints Wayne J. Riley, M.D., to its Board of Directors - BusinessWire | | | MONDAY, JULY 12, 2010 | | 9:28 AM | Vertex Pharmaceuticals Announces the Date of its Second Quarter 2010 Financial Results Conference Call and Webcast - BusinessWire | | | THURSDAY, JUNE 17, 2010 | | 9:00 AM | One Year After the Launch of Telaprevir and Boceprevir, Surveyed Physicians Expect to Prescribe Triple Therapy Regimens to 90 Percent of Their Hepatitis C Virus Patients - PR Newswire | | | FRIDAY, JUNE 11, 2010 | | 4:15 PM | Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences - BusinessWire | |
|
|
|
